The government plans to fix TMR in a phased manner and has identified 139 formulations which include drugs like Remdesivir, Tocilizumab, influenza drugs, some patented drugs, among others.
The list has been sent to the health minister Mansukh Mandaviya after it was vetted by various government bodies including-the National Pharmaceutical Pricing Authority (NPPA), Central Drugs Standard Control Organisation (CDSCO, All India Institute of Medical Sciences (AIIMS), Directorate General of Health Services (DGHS). “A list was prepared by the Department of Pharmaceuticals (DoP) which went through changes after it was being vetted by various government bodies. A list of 139 formulations has not been submitted for consideration for TMR,” said a senior official.
It has been suggested that TMR be capped between 33% and 50% on price to distributors, the same person said.
Earlier in 2019 the government had slashed the prices of cancer drugs with provision of 30% margin to the trade channel, indicating that the move is a pilot for more drugs and medical devices in the future. “It will be scaled up and we are actively working on the same,” said a senior government official. Trade margin is the difference between the price at which the manufacturers/importers sell to stockists and the price charged to consumers.
Meanwhile, several pharma companies have expressed their concerns over the government’s move to implement TMR.